Neuromuscular Disease Unit / ALS Clinic St. Gallen

Kantonsspital St. Gallen

The ALS Clinic in St. Gallen is the major referral center for ALS patients in Switzerland.

st. gallen
Kantonsspital St. Gallen

We offer multidisciplinary patient care to 200 patients from all over Switzerland. Patients are seen on a regular basis, usually every three months. In addition, we are engaged in numerous research projects. These cover a broad spectrum reaching from quality of life research to genetic research. Most of the projects are collaborations with other ALS/MND centers. Clinical neurophysiology is a corner stone in our routine clinical practice and also in some research projects. Our mission is to provide holistic care to ALS patients and caregivers and to contribute to ALS research.

Contact
Location
Rorschacher Strasse, St. Gallen, Switzerland

Our Specialists

Markus Weber

Professor of Neurology

Markus Weber is Professor of Neurology in Kantonsspital St. Gallen

Markus Weber
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more